Atherogenic lipids induce adhesion of human coronary artery smooth muscle cells to macrophages by up-regulating chemokine CX3CL1 on smooth muscle cells in a TNFα-NFκB-dependent manner

被引:50
作者
Barlic, Jana [1 ]
Zhang, Yuan [1 ]
Murphy, Philip M. [1 ]
机构
[1] NIH, NIAID, Mol Signalling Sect, Lab Mol Immunol, Bethesda, MD 20892 USA
关键词
D O I
10.1074/jbc.M701642200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent genetic evidence has implicated the adhesive chemokine CX3CL1 and its leukocyte receptor CX3CR1 in atherosclerosis. We previously proposed a mechanism involving foam cell anchorage to vascular smooth muscle cells because: 1) CX3CL1 and CX3CR1 are expressed by both cell types in mouse and human atherosclerotic lesions; 2) foam cells are reduced in lesions in cx3cr1(-/-) apoE(-/-) mice; and 3) proatherogenic lipids ( oxidized low density lipoprotein [oxLDL] and oxidized linoleic acid derivatives) induce adhesion of primary human macrophages to primary human coronary artery smooth muscle cells (CASMCs) in vitro in a macrophage CX3CR1-dependent manner. Here we analyze this concept further by testing whether atherogenic lipids regulate expression and function of CX3CL1 and CX3CR1 on CASMCs. We found that both oxLDL and oxidized linoleic acid derivatives indirectly up-regulated CASMC CX3CL1 at both the protein and mRNA levels through an autocrine feedback loop involving tumor necrosis factor alpha production and NF-kappa B signaling. Oxidized lipids also up-regulated CASMC CX3CR1 but through a different mechanism. Oxidized lipid stimulation also increased adhesion of macrophages to CASMCs when CASMCs were stimulated prior to assay, and a synergistic pro-adhesive effect was observed when both cell types were prestimulated. Selective inhibition with a CX3CL1-specific blocking antibody indicated that adhesion was strongly CASMC CX3CL1-dependent. These findings support the hypothesis that CX3CR1 and CX3CL1 mediate heterotypic anchorage of foam cells to CASMCs in the context of atherosclerosis and suggest that this chemokine/chemokine receptor pair may be considered as a pro-inflammatory target for therapeutic intervention in atherosclerotic cardiovascular disease.
引用
收藏
页码:19167 / 19176
页数:10
相关论文
共 56 条
[1]  
Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO
[2]  
2
[3]   Oxidized lipid-driven chemokine receptor switch, CCR2 to CX3CR1, mediates adhesion of human macrophages to coronary artery smooth muscle cells through a peroxisome proliferator-activated receptor γ-dependent pathway [J].
Barlic, Jana ;
Zhang, Yuan ;
Foley, John F. ;
Murphy, Philip M. .
CIRCULATION, 2006, 114 (08) :807-819
[4]   A new class of membrane-bound chemokine with a CX(3)C motif [J].
Bazan, JF ;
Bacon, KB ;
Hardiman, G ;
Wang, W ;
Soo, K ;
Rossi, D ;
Greaves, DR ;
Zlotnik, A ;
Schall, TJ .
NATURE, 1997, 385 (6617) :640-644
[5]   NF-κB family of transcription factors:: Central regulators of innate and adaptive immune functions [J].
Caamaño, J ;
Hunter, CA .
CLINICAL MICROBIOLOGY REVIEWS, 2002, 15 (03) :414-+
[6]   Fractalkine (CX3CL1) stimulated by nuclear factor κB (NF-κB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway [J].
Chandrasekar, B ;
Mummidi, S ;
Perla, RP ;
Bysani, S ;
Dulin, NO ;
Liu, F ;
Melby, PC .
BIOCHEMICAL JOURNAL, 2003, 373 :547-558
[7]   Mechanisms of disease - The many roles of chemokines and chemokine receptors in inflammation [J].
Charo, IF ;
Ransohoff, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (06) :610-621
[8]   Chemokines in the pathogenesis of vascular disease [J].
Charo, IF ;
Taubman, MB .
CIRCULATION RESEARCH, 2004, 95 (09) :858-866
[9]   Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice [J].
Combadière, C ;
Potteaux, S ;
Gao, JL ;
Esposito, B ;
Casanova, S ;
Lee, EJ ;
Debré, P ;
Tedgui, A ;
Murphy, PM ;
Mallat, Z .
CIRCULATION, 2003, 107 (07) :1009-1016
[10]   Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy [J].
Damås, JK ;
Boullier, A ;
Wæhre, T ;
Smith, C ;
Sandberg, WJ ;
Green, S ;
Aukrust, P ;
Quehenberger, O .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (12) :2567-2572